S.C. Sintofarm (SINT) Stock Overview
Manufactures and sells pharmaceutical preparations in Romania. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SINT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
S.C. Sintofarm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RON 7.00 |
| 52 Week High | RON 10.00 |
| 52 Week Low | RON 3.50 |
| Beta | -0.021 |
| 1 Month Change | -23.50% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 38.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| SINT | RO Pharmaceuticals | RO Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 2.0% |
| 1Y | n/a | 22.5% | 56.2% |
Return vs Industry: Insufficient data to determine how SINT performed against the RO Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SINT performed against the RO Market.
Price Volatility
| SINT volatility | |
|---|---|
| SINT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in RO Market | 10.7% |
| 10% least volatile stocks in RO Market | 3.2% |
Stable Share Price: SINT's share price has been volatile over the past 3 months compared to the RO market.
Volatility Over Time: Insufficient data to determine SINT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1916 | 47 | n/a | sintofarm.ro |
S.C. Sintofarm S.A. manufactures and sells pharmaceutical preparations in Romania. The company offers medicines for human use; medical devices; cosmetic products; biocidal disinfectants; food supplements; and other chemical products. It engages in research and exploitation; and import and export activities.
S.C. Sintofarm S.A. Fundamentals Summary
| SINT fundamental statistics | |
|---|---|
| Market cap | RON 27.03m |
| Earnings (TTM) | RON 327.02k |
| Revenue (TTM) | RON 12.91m |
Is SINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SINT income statement (TTM) | |
|---|---|
| Revenue | RON 12.91m |
| Cost of Revenue | RON 2.98m |
| Gross Profit | RON 9.93m |
| Other Expenses | RON 9.60m |
| Earnings | RON 327.02k |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.085 |
| Gross Margin | 76.94% |
| Net Profit Margin | 2.53% |
| Debt/Equity Ratio | 0% |
How did SINT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 11:26 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
S.C. Sintofarm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.